128 related articles for article (PubMed ID: 37852628)
1. Proposal to distinguish HER2-low from HER2-normal breast cancer by in situ hybridisation.
Chen YY; Yang CF; Hsu CY
J Clin Pathol; 2023 Nov; 76(11):753-756. PubMed ID: 37852628
[TBL] [Abstract][Full Text] [Related]
2. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
3. Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study.
Memon R; Prieto Granada CN; Harada S; Winokur T; Reddy V; Kahn AG; Siegal GP; Wei S
Clin Breast Cancer; 2022 Jan; 22(1):e123-e133. PubMed ID: 34120846
[TBL] [Abstract][Full Text] [Related]
4. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
6. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
7. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
8. UK recommendations for HER2 assessment in breast cancer: an update.
Rakha EA; Tan PH; Quinn C; Provenzano E; Shaaban AM; Deb R; Callagy G; Starczynski J; Lee AHS; Ellis IO; Pinder SE
J Clin Pathol; 2023 Apr; 76(4):217-227. PubMed ID: 36564170
[TBL] [Abstract][Full Text] [Related]
9. Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy.
Gibbons-Fideler IS; Nitta H; Murillo A; Tozbikian G; Banks P; Parwani AV; Li Z
Am J Clin Pathol; 2019 Jan; 151(2):176-184. PubMed ID: 30339245
[TBL] [Abstract][Full Text] [Related]
10. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
11. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quantification with in situ hybridization assay.
Polónia A; Canelas C; Caramelo A
Virchows Arch; 2022 Jun; 480(6):1171-1179. PubMed ID: 35137279
[TBL] [Abstract][Full Text] [Related]
13. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.
Sandén E; Khazaei S; Tryggvadottir H; Borgquist S; Isaksson K; Jirström K; Jernström H
Virchows Arch; 2020 Aug; 477(2):317-320. PubMed ID: 32080761
[TBL] [Abstract][Full Text] [Related]
15. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
16. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Wolff AC; Somerfield MR; Dowsett M; Hammond MEH; Hayes DF; McShane LM; Saphner TJ; Spears PA; Allison KH
Arch Pathol Lab Med; 2023 Sep; 147(9):993-1000. PubMed ID: 37303228
[TBL] [Abstract][Full Text] [Related]
17. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
Curado M; Caramelo AS; Eloy C; Polónia A
Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
[TBL] [Abstract][Full Text] [Related]
18. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
20. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]